Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
800 | 800 | 14,089,517 | 1,633 | Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or ... | 1.-4. (canceled) 5. A composition, comprising:
(a) at least 2 V gene segment primers, and (b) at least 2 J gene segment primers,
each of said at least 2 V gene segment primers being capable of annealing to V gene segment sequence and amplifying V gene segment sequence, and each of said at least 2 J gene segment primers... | Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or ... | 1,600 |
801 | 801 | 14,915,517 | 1,617 | The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a polysaccharide modified with hydrophobic chains; a polymer comprising sulfonic groups; a (meth)acrylic acid polymer, which is preferably crosslinked, and/or an oxyethylenated silicone surfactant.
Use for ... | 1. A composition, comprising, in a physiologically acceptable aqueous medium:
i) at least one polymer comprising a sulfonic group; ii) at least one polysaccharide modified with hydrophobic chains; and iii) at least one (meth)acrylic acid polymer, silicone surfactant which is an oxyethylenated polydimethylsiloxane, or b... | The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a polysaccharide modified with hydrophobic chains; a polymer comprising sulfonic groups; a (meth)acrylic acid polymer, which is preferably crosslinked, and/or an oxyethylenated silicone surfactant.
Use for ... | 1,600 |
802 | 802 | 13,700,175 | 1,615 | The present invention relates to balloon catheters with or without crimped stent, whose surface is coated with at least one antirestenotic agent and at least one transport promoting molecular dispersant, as well as a method for the preparation of these medical devices. | 1.-15. (canceled) 16. A catheter balloon with or without crimped stent, wherein the surface of the catheter balloon is coated at least partially with at least one antirestenotic agent and at least one transport promoting molecular dispersant, wherein the at least one transport promoting molecular dispersant is at least... | The present invention relates to balloon catheters with or without crimped stent, whose surface is coated with at least one antirestenotic agent and at least one transport promoting molecular dispersant, as well as a method for the preparation of these medical devices.1.-15. (canceled) 16. A catheter balloon with or wi... | 1,600 |
803 | 803 | 14,912,776 | 1,631 | Automated methods of preparing patient samples for assays are disclosed. The methods include performing sample processing of multiple patient samples in multiple extraction wells of an extraction plate to prepare multiple eluded samples in at least some of the multiple extraction wells, and transferring, based upon an ... | 1. A method of preparing samples for assaying on a test plate having a plurality of wells, comprising:
receiving, via a user interface, instructions to run a first assay type and a second assay type; determining sample identifications for a plurality of samples to be assayed; receiving assay orders corresponding to the... | Automated methods of preparing patient samples for assays are disclosed. The methods include performing sample processing of multiple patient samples in multiple extraction wells of an extraction plate to prepare multiple eluded samples in at least some of the multiple extraction wells, and transferring, based upon an ... | 1,600 |
804 | 804 | 14,281,638 | 1,618 | Various agents and additives for cross-linking treatments are identified in disclosed studies. The characteristics of the various agents and additives may be advantageously employed in formulations applied in cross-linking treatments of the eye. In some embodiments, riboflavin is combined with Iron(II) to enhance the c... | 1. A composition for applying therapy to a cornea of an eye, comprising:
a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photo-activating light; and at least one additive different from the cross-linking agent and selected from the group consisting of iron, copper,... | Various agents and additives for cross-linking treatments are identified in disclosed studies. The characteristics of the various agents and additives may be advantageously employed in formulations applied in cross-linking treatments of the eye. In some embodiments, riboflavin is combined with Iron(II) to enhance the c... | 1,600 |
805 | 805 | 15,121,944 | 1,651 | A method and system of preparing a sample for microbial testing by providing a sample in a sample bag, a dry sterile growth medium in a bag, and a source of pure (Type II) water heated to a temperature of about 25-50° C., homogenizing the sample, reconstituting the dry medium with the heated Type II water, mixing the m... | 1. A method of performing a microbiological test on a semi-solid and/or solid sample comprising the steps of:
a. providing a sample to be tested, b. providing dehydrated growth medium, c. providing a source of pure (Type II) water heated to a temperature of about 25-50° C. d. homogenizing the sample, e. reconstituting ... | A method and system of preparing a sample for microbial testing by providing a sample in a sample bag, a dry sterile growth medium in a bag, and a source of pure (Type II) water heated to a temperature of about 25-50° C., homogenizing the sample, reconstituting the dry medium with the heated Type II water, mixing the m... | 1,600 |
806 | 806 | 13,863,001 | 1,611 | A concentrated liquid sanitizing and rinse composition containing peroxycarboxylic acid(s) and compatible rinse aid surfactants is disclosed. The sanitizing and rinsing compositions are formulated in a single liquid concentrate, replacing a traditional dual product of a sanitizer and rinse aid. The sanitizing and rinsi... | 1. A sanitizing rinse additive composition comprising:
a C1-C22 peroxycarboxylic acid; a C1-C22 carboxylic acid; hydrogen peroxide; and a nonionic defoaming and wetting surfactant(s); wherein the composition is a low odor concentrate having less than about 2 wt-% peroxyacetic and peracid acid, and wherein the compositi... | A concentrated liquid sanitizing and rinse composition containing peroxycarboxylic acid(s) and compatible rinse aid surfactants is disclosed. The sanitizing and rinsing compositions are formulated in a single liquid concentrate, replacing a traditional dual product of a sanitizer and rinse aid. The sanitizing and rinsi... | 1,600 |
807 | 807 | 16,013,552 | 1,649 | Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin... | 1. A method of treating and/or retarding progression of dry macular degeneration in a patient, the method comprising:
identifying a patient with dry macular degeneration; and injecting a botulinum neurotoxin into a periorbital or a para orbital region of the patient, but not into an intra-ocular or a subconjunctival re... | Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin... | 1,600 |
808 | 808 | 14,698,698 | 1,658 | Protein supplements that include proteins from animal products, such as whey and eggs, are disclosed. Such a protein supplement may also include one or more immune modulators, such as transfer factor and/or nanofraction immune modulators. | 1. A protein supplement, including:
an animal-based protein hydrolysate; and an immune modulator. 2. The protein supplement of claim 1, wherein the immune modulator is from a source other than the animal-based protein hydrolysate. 3. The protein supplement of claim 1, wherein the animal-based protein hydrolysate compri... | Protein supplements that include proteins from animal products, such as whey and eggs, are disclosed. Such a protein supplement may also include one or more immune modulators, such as transfer factor and/or nanofraction immune modulators.1. A protein supplement, including:
an animal-based protein hydrolysate; and an im... | 1,600 |
809 | 809 | 15,050,343 | 1,642 | The present invention provides assays and methods for determining an individual's risk of developing colorectal cancer (CRC) by analyzing a pre-cancerous polyp tissue sample. The present invention also provides assay and methods for selecting an anti-cancer therapeutic drug for an individual diagnosed as having early s... | 1. A method for diagnosing the risk of developing colorectal cancer (CRC) in a subject, the method comprising:
a) lysing a cell from a polyp sample taken from the subject to form a cell lysate; b) measuring the activation and/or expression level of the at least one signal transduction analyte in the cell lysate; c) ind... | The present invention provides assays and methods for determining an individual's risk of developing colorectal cancer (CRC) by analyzing a pre-cancerous polyp tissue sample. The present invention also provides assay and methods for selecting an anti-cancer therapeutic drug for an individual diagnosed as having early s... | 1,600 |
810 | 810 | 13,203,365 | 1,613 | Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inh... | 1. A method of treatment or prophylaxis of a glaucoma or elevated intraocular pressure comprising administering an effective amount of a PDE 1 inhibitor, or a combination of the PDE 1 inhibitor and an intraocular pressure-lowering agent, to a patient in need thereof. 2. The method of claim 1 wherein the PDE 1 inhibitor... | Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inh... | 1,600 |
811 | 811 | 15,834,491 | 1,649 | Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin... | 1. A method of treating age-related macular degeneration, the method comprising:
administering a botulinum neurotoxin or a fragment thereof to a human or mammalian patient suffering from or at risk for macular degeneration. 2. The method of claim 1, wherein the administration of the botulinum neurotoxin mitigates wet a... | Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin... | 1,600 |
812 | 812 | 14,898,810 | 1,611 | A synergistic preservative composition comprises sorbic acid or a salt thereof, benzyl alcohol, and a mixture of (i) 1,2-propanediol and/or 1,3-propanediol, and (ii), 4-butanediol and/or 1,3-butanediol. The composition is particularly suited for the preservation of cosmetics and personal care products. | 1. A preservative composition comprising
(a) from 1 to 20 wt. % of sorbic acid or a salt thenqgf hereof; (b) from 10 to 89 wt. % of benzyl alcohol; (c) from 10 to 89 wt. % of a mixture of
(i) 1,2-propanediol, 1,3-propanediol, or a mixture thereof; and
(ii) 1,4-butanediol, 1,3-butanediol, or a mixture thereof
in a weigh... | A synergistic preservative composition comprises sorbic acid or a salt thereof, benzyl alcohol, and a mixture of (i) 1,2-propanediol and/or 1,3-propanediol, and (ii), 4-butanediol and/or 1,3-butanediol. The composition is particularly suited for the preservation of cosmetics and personal care products.1. A preservative... | 1,600 |
813 | 813 | 16,012,961 | 1,618 | Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilize... | 1. A soft gelatin capsule comprising a fill material comprising:
(a) a naproxen salt; (b) a deionizing agent comprising lactic acid in an amount of from 0.2 to 1.0 mole equivalents per mole of naproxen salt; (c) polyethylene glycol; and (d) one or more solubilizers. 2. The capsule of claim 1, wherein the naproxen salt ... | Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilize... | 1,600 |
814 | 814 | 14,851,352 | 1,619 | The present invention relates to the use of at least one 2-methylsuccinic acid diester derivative of formula (I) below:
in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at lea... | 1. A composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase, characterized in that it contains at least one 2-methylsuccinic acid diester derivative of formula (I) and/or an optical isomer and/or solvate thereof of formula (I) below:
in which:
R1 and R2, which may be iden... | The present invention relates to the use of at least one 2-methylsuccinic acid diester derivative of formula (I) below:
in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at lea... | 1,600 |
815 | 815 | 15,167,730 | 1,657 | Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde. | 1. A packaged bioprosthetic device comprising:
a dry collagenous tissue comprising at least first and second sets of crosslinkages, wherein the first set of crosslinkages is provided between free amine functional groups on the collagenous tissue, wherein the second set of crosslinkages is provided between free aldehyde... | Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.1. A p... | 1,600 |
816 | 816 | 14,173,461 | 1,641 | A system and method of quantitating the concentration of a molecule of interest in one embodiment includes establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curve... | 1. A method of quantitating the concentration of a molecule of interest comprising:
establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curves different from the ot... | A system and method of quantitating the concentration of a molecule of interest in one embodiment includes establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curve... | 1,600 |
817 | 817 | 15,440,628 | 1,641 | Methods include determining in a sample an amount of a first isomeric analyte and a second isomeric analyte. A first measurement value and a second measurement value are determined. The first measurement value represents a total amount of the first isomeric analyte and the second isomeric analyte. The second measuremen... | 1-20. (canceled) 21. A method of determining in a sample an amount of non-epi-25-hydroxy vitamin D3 and 3-epi 25-hydroxy vitamin D3, the method comprising:
(a) conducting an assay on a first portion of the sample using an assay protocol wherein assay reagents utilized in the assay protocol of this step (a) comprise vit... | Methods include determining in a sample an amount of a first isomeric analyte and a second isomeric analyte. A first measurement value and a second measurement value are determined. The first measurement value represents a total amount of the first isomeric analyte and the second isomeric analyte. The second measuremen... | 1,600 |
818 | 818 | 14,029,376 | 1,617 | Ready-to-use foamable pesticide compositions that contain a particulate pesticide suspended therein and applicators for dispensing such compositions. Methods for treating pests such as arthropods by contacting pests with such compositions are also provided. | 1. A ready-to-use foamable pesticide composition comprising:
a diluent; a particulate pesticide suspended in the diluent; a thickening agent; and a surfactant system comprising at least one fatty acid soap. 2. A ready-to-use foamable pesticide composition as set forth in claim 1 wherein the particulate pesticide is an ... | Ready-to-use foamable pesticide compositions that contain a particulate pesticide suspended therein and applicators for dispensing such compositions. Methods for treating pests such as arthropods by contacting pests with such compositions are also provided.1. A ready-to-use foamable pesticide composition comprising:
a ... | 1,600 |
819 | 819 | 14,921,898 | 1,618 | The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I)
or a pharmaceutically acceptable salt thereof, the pr... | 1. A preparation comprising a polymer, the polymer comprising a monomer of formula (I):
or a pharmaceutically acceptable salt thereof, wherein leachable tin is present in the preparation at a level within a range of about 0 ppm to about 150 ppm. 2. The preparation of claim 1, wherein the pharmaceutically acce... | The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I)
or a pharmaceutically acceptable salt thereof, the pr... | 1,600 |
820 | 820 | 14,846,290 | 1,631 | Systems and methods for genomic analysis are contemplated in which idiosyncratic markers or marker constellations are employed to characterize and compare genomic sequences. In especially preferred aspects, the idiosyncratic markers are predetermined SNPs and a marker profile is used in a sample record to so allow cros... | 1. A method of analyzing a genomic sequence of a target tissue of a mammal, comprising:
coupling an analysis engine to a sequence database that stores a genomic sequence for the target tissue of the mammal; characterizing, by the analysis engine, a plurality of predetermined idiosyncratic markers in the genomic sequenc... | Systems and methods for genomic analysis are contemplated in which idiosyncratic markers or marker constellations are employed to characterize and compare genomic sequences. In especially preferred aspects, the idiosyncratic markers are predetermined SNPs and a marker profile is used in a sample record to so allow cros... | 1,600 |
821 | 821 | 14,905,990 | 1,619 | The present invention belongs to the field of pharmaceutical industry and relates to an amorphous solid dispersion comprising at least one polymer and dapagliflozin, to a pharmaceutical composition comprising said solid dispersion, to a process for the preparation thereof, and to the solid dispersion and pharmaceutical... | 1. Amorphous solid dispersion of at least one suitable polymer and dapagliflozin ((2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol) of formula 1
wherein the at least one polymer is selected from the group consisting of polyvinyl pyrrolidone (PVP), polyv... | The present invention belongs to the field of pharmaceutical industry and relates to an amorphous solid dispersion comprising at least one polymer and dapagliflozin, to a pharmaceutical composition comprising said solid dispersion, to a process for the preparation thereof, and to the solid dispersion and pharmaceutical... | 1,600 |
822 | 822 | 15,283,751 | 1,615 | Provided herein are portable application devices and compositions for nasal and oral delivery of substances and compositions to treat overdose, addiction and/or behavioral disordered persons. | 1. A pharmaceutical formulation in the form of liquid solution for spray administration by the nasal and/or buccal route containing naltrexone and/or nalmefene as the active ingredient in amounts greater than 1% effective to block and/or reverse physiological effects of mixtures of opiates and opioids, including heroin... | Provided herein are portable application devices and compositions for nasal and oral delivery of substances and compositions to treat overdose, addiction and/or behavioral disordered persons.1. A pharmaceutical formulation in the form of liquid solution for spray administration by the nasal and/or buccal route containi... | 1,600 |
823 | 823 | 14,766,913 | 1,644 | The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determi... | 1. A particulate entity comprising:
i. an invariant Natural Killer T (iNKT) cell agonist, ii. optionally, one or more antigenic determinant(s), and, iii. a targeting agent that targets in vivo said iNKT cell agonist, to dendritic cells. 2. The particulate entity of claim 1, wherein said targeting agent targets said iNK... | The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determi... | 1,600 |
824 | 824 | 15,487,263 | 1,628 | The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertensi... | 1. A method of treating a cardiovascular condition in a subject, said method comprising:
administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space located at one or more of the first through fourth thoracic vertebral level of the subject. 2. The method of claim 1, wherein th... | The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertensi... | 1,600 |
825 | 825 | 15,960,886 | 1,619 | Methods and compositions for enhancing plant characteristics of leguminous and non-leguminous crops include combination treatments with at least one fungicide, insecticide, or combination thereof, and one or more plant inducers, such as nod factors. Optionally, an inoculant composition may be used with the invention to... | 1. A method of enhancing plant yield, said method comprising treating a seed and/or the plant that grows from said seed with a composition comprising:
a lipo-chitooligosaccharide; and an insecticide comprising imidacloprid, thiamethoxam and/or clothiandidin said lipo-chitooligosaccharide and said insecticide present in... | Methods and compositions for enhancing plant characteristics of leguminous and non-leguminous crops include combination treatments with at least one fungicide, insecticide, or combination thereof, and one or more plant inducers, such as nod factors. Optionally, an inoculant composition may be used with the invention to... | 1,600 |
826 | 826 | 12,274,765 | 1,653 | The present invention is directed to methods of cryopreserving cells and cryopreserved cells prepared according to the methods. In specific embodiments, the method comprises combining cells with a cross-linked hydrogel matrix in particulate form, the matrix comprising a polyglycan cross-linked to a polypeptide and subj... | 1. A method of cryopreserving cells comprising subjecting to cryopreservation conditions particles of a cross-linked bioactive hydrogel matrix, said hydrogel matrix particles retaining cells for cryopreservation. 2. The method of claim 1, wherein said step of subjecting to cryopreservation conditions comprises introduc... | The present invention is directed to methods of cryopreserving cells and cryopreserved cells prepared according to the methods. In specific embodiments, the method comprises combining cells with a cross-linked hydrogel matrix in particulate form, the matrix comprising a polyglycan cross-linked to a polypeptide and subj... | 1,600 |
827 | 827 | 15,411,211 | 1,612 | Disclosed are therapeutic oral compositions useful in the treatment of a variety of oral disorders, in which the composition can provide blockage of dentinal tubes, while at the same time provide antibacterial and anti-caries efficacy. The compositions include arginine in free or salt form, a mucoadhesive polymer, and ... | 1-20. (canceled) 21. An oral care composition comprising at least one arginine compound in free or salt form, at least one mucoadhesive polymer, and at least one component selected from the group consisting of pyrophosphate compounds, zinc salts, potassium salts, strontium salts, and mixtures thereof, wherein the argin... | Disclosed are therapeutic oral compositions useful in the treatment of a variety of oral disorders, in which the composition can provide blockage of dentinal tubes, while at the same time provide antibacterial and anti-caries efficacy. The compositions include arginine in free or salt form, a mucoadhesive polymer, and ... | 1,600 |
828 | 828 | 14,595,695 | 1,612 | A phospholipid microbubble comprising a shell which comprises a plurality of polyunsaturated fatty acid (“PUFA”)-containing phospholipids, and a core of paramagnetic gas surrounded by the shell comprising the plurality of PUFA-containing phospholipids. The present invention also provides methods of delivering a prophyl... | 1. A phospholipid microbubble comprising a shell which comprises a plurality of polyunsaturated fatty acid (“PUFA”)-containing phospholipids, and a core of paramagnetic gas surrounded by said shell comprising said plurality of PUFA-containing phospholipids. 2. The phospholipid microbubble of claim 1, wherein said plura... | A phospholipid microbubble comprising a shell which comprises a plurality of polyunsaturated fatty acid (“PUFA”)-containing phospholipids, and a core of paramagnetic gas surrounded by the shell comprising the plurality of PUFA-containing phospholipids. The present invention also provides methods of delivering a prophyl... | 1,600 |
829 | 829 | 13,380,839 | 1,631 | An electronic system is provided that simulates a glucose-insulin metabolic system of a T2DM or prediabetic subject, wherein the system includes a subsystem that models dynamic glucose concentration in a T2DM or prediabetic subject, including an electronic module that models endogenous glucose production (EGP(t)), or m... | 1. An electronic system that simulates a glucose-insulin metabolic system of a T2DM or prediabetic subject, comprising:
a subsystem that models dynamic glucose concentration in a T2DM or prediabetic subject, including
an electronic module that models endogenous glucose production (EGP(t)),
an electronic module that mod... | An electronic system is provided that simulates a glucose-insulin metabolic system of a T2DM or prediabetic subject, wherein the system includes a subsystem that models dynamic glucose concentration in a T2DM or prediabetic subject, including an electronic module that models endogenous glucose production (EGP(t)), or m... | 1,600 |
830 | 830 | 14,163,948 | 1,613 | Disclosed herein are embodiments of a composition useful for treating and/or preventing dry eye disorders. The disclosed composition comprises components that maintain the composition's chemical and/or physical properties thereby providing a composition suitable for use. | 1. A composition for ophthalmic administration, comprising greater than 2% w/v to about 15% w/v polyvinylpyrrolidone. 2. The composition of claim 1, wherein the polyvinylpyrrolidone has an average molecular weight of from about 40,000 to about 60,000. 3. The composition of claim 1, wherein the polyvinylpyrrolidone cont... | Disclosed herein are embodiments of a composition useful for treating and/or preventing dry eye disorders. The disclosed composition comprises components that maintain the composition's chemical and/or physical properties thereby providing a composition suitable for use.1. A composition for ophthalmic administration, c... | 1,600 |
831 | 831 | 12,479,576 | 1,612 | The present invention is directed to methods of treating nasal and/or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to metho... | 1. A method for treating an allergic symptom or disorder in a subject in need thereof, comprising: nasally administering to the subject a corticosteroid solution comprising a therapeutically effective amount of a corticosteroid, SAE-CD, and a pharmaceutically acceptable aqueous liquid carrier,
wherein the allergic symp... | The present invention is directed to methods of treating nasal and/or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to metho... | 1,600 |
832 | 832 | 15,515,193 | 1,617 | This invention provides for a solid, particulate insecticidal formulation in the form of a granule, a bait or a tablet for mechanical incorporation into or onto soil comprising a volatile insecticidal active ingredient that is microencapsulated and combined with a bulking agent and a disintegrating agent. The solid par... | 1. A solid particulate insecticidal formulation which is formulated to be mechanically incorporated into or onto soil, the formulation comprising:
i. a microencapsulated volatile insecticide selected from insecticidal active ingredients having:
(a) a vapour pressure at 25° C. in the range from about 1 mPa to about 1,00... | This invention provides for a solid, particulate insecticidal formulation in the form of a granule, a bait or a tablet for mechanical incorporation into or onto soil comprising a volatile insecticidal active ingredient that is microencapsulated and combined with a bulking agent and a disintegrating agent. The solid par... | 1,600 |
833 | 833 | 14,243,466 | 1,616 | Disclosed herein is a powder composition containing an alkaline material comprising hydroxide-containing compounds, a starch, a silica material, a liquid fatty substance, an acrylic polymer, wax, and a chelant compound. When the powder composition is mixed with an aqueous composition, a ready to use composition for rel... | 1. A powder composition comprising:
(a) from about 1% to about 30% by weight of active material of at least one alkaline material comprising at least one hydroxide-containing compound selected from alkali metal hydroxides, alkaline-earth metal hydroxides, transition metal hydroxides, and mixtures thereof; (b) from abou... | Disclosed herein is a powder composition containing an alkaline material comprising hydroxide-containing compounds, a starch, a silica material, a liquid fatty substance, an acrylic polymer, wax, and a chelant compound. When the powder composition is mixed with an aqueous composition, a ready to use composition for rel... | 1,600 |
834 | 834 | 14,504,893 | 1,653 | A method for monitoring a reaction and a reaction system are provided. The reaction system includes at least one vessel for the reaction medium, which is in fluid communication with an injection tube; at least one vessel for a carrier fluid that is immiscible with the reaction medium, which is in fluid communication wi... | 1. A reaction system, notably of cultures of microorganisms, comprising:
at least one reservoir of reaction mixture fluidically connected to a capillary injection tube; at least one reservoir of a carrier fluid that is immiscible with the reaction mixture, fluidically connected to a capillary reaction tube, the capilla... | A method for monitoring a reaction and a reaction system are provided. The reaction system includes at least one vessel for the reaction medium, which is in fluid communication with an injection tube; at least one vessel for a carrier fluid that is immiscible with the reaction medium, which is in fluid communication wi... | 1,600 |
835 | 835 | 14,134,342 | 1,644 | A method can include administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient where the antibody is an immunoglobulin G subclass 4 antibody (G4). Various other examples of devices, assemblies, systems, methods, etc., are also disclosed. | 1. A method comprising:
administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient wherein the antibody comprises an immunoglobulin G subclass 4 antibody (G4). 2. The method of claim 1 comprising monitoring level of G4 in the recipient. 3. The method of claim 2 comprising repeating... | A method can include administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient where the antibody is an immunoglobulin G subclass 4 antibody (G4). Various other examples of devices, assemblies, systems, methods, etc., are also disclosed.1. A method comprising:
administering a dono... | 1,600 |
836 | 836 | 15,548,964 | 1,616 | The invention relates to microcapsules comprising at least one active substance selected from lutein and lutein esters embedded in a matrix comprising gum acacia and optionally one or more other matrix components, wherein the content of said at least one active substance calculated as free lutein is from 0.5 to 25% of ... | 1.-18. (canceled) 19. A microcapsule comprising at least one active substance selected from lutein and lutein esters embedded in a matrix comprising native gum acacia and optionally one or more other matrix components, wherein the content of said at least one active substance calculated as free lutein is from 0.5 to 25... | The invention relates to microcapsules comprising at least one active substance selected from lutein and lutein esters embedded in a matrix comprising gum acacia and optionally one or more other matrix components, wherein the content of said at least one active substance calculated as free lutein is from 0.5 to 25% of ... | 1,600 |
837 | 837 | 15,561,763 | 1,612 | Provided is a dental membrane which includes: a first support made by accumulating first nanofibers of a biodegradable polymer obtained by electrospinning and having a plurality of pores formed therein; a second support made by accumulating second nanofibers of a biodegradable polymer obtained by electrospinning on the... | 1. A dental membrane comprising:
a first support made by accumulating first nanofibers of a biodegradable polymer obtained by electrospinning and having a plurality of pores formed therein; a second support made by accumulating second nanofibers of a biodegradable polymer obtained by electrospinning on the first suppor... | Provided is a dental membrane which includes: a first support made by accumulating first nanofibers of a biodegradable polymer obtained by electrospinning and having a plurality of pores formed therein; a second support made by accumulating second nanofibers of a biodegradable polymer obtained by electrospinning on the... | 1,600 |
838 | 838 | 15,037,978 | 1,649 | The invention provides methods of monitoring immunotherapy directed against alpha-synuclein by comparing a subject's constipation symptoms before treatment and at one or more times during and/or after treatment. The immunotherapeutic regime can be monitored depending on the results of treatment. | 1. A method of assessing the efficacy of immunotherapy against alpha-synuclein in subjects diagnosed with a Lewy Body disease and having one or more constipation symptoms, comprising:
(a) evaluating the subjects' constipation symptoms before administration of an immunotherapeutic agent in a first regime; (b) administer... | The invention provides methods of monitoring immunotherapy directed against alpha-synuclein by comparing a subject's constipation symptoms before treatment and at one or more times during and/or after treatment. The immunotherapeutic regime can be monitored depending on the results of treatment.1. A method of assessing... | 1,600 |
839 | 839 | 15,397,193 | 1,633 | A biodegradable cationic polymer is disclosed, comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a subunit derived from a monomeric diol initiator for... | 1. A polymer complex, comprising:
a negatively charged biologically active material selected from the group consisting of genes, nucleotides, proteins, peptides, drugs, and combinations thereof; and a biodegradable cationic polymer comprising two polymer chains joined by a divalent linking group, wherein each of the po... | A biodegradable cationic polymer is disclosed, comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a subunit derived from a monomeric diol initiator for... | 1,600 |
840 | 840 | 15,921,596 | 1,658 | Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided. | 1. A method for preventing, improving, or treating inflammatory bowel disease, which comprises administering to a subject in need a composition containing, as an active component, a compound represented by the following Formula 1, an optical isomer thereof, or a salt thereof:
wherein:
n is 0, 1, or 2;
A is -a... | Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.1. A method for preventing, improving, or treating inflammatory bowel d... | 1,600 |
841 | 841 | 15,205,853 | 1,658 | Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided. | 1. A compound represented by the following Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
wherein:
n is 0, 1, or 2;
A is -a1-, which is an amino acid independently selected from the group consisting of alanine, (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic ac... | Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.1. A compound represented by the following Formula 1, an optical isomer... | 1,600 |
842 | 842 | 13,377,514 | 1,643 | The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic... | 1. A method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the... | The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic... | 1,600 |
843 | 843 | 15,950,246 | 1,628 | Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors or to treat viruses, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or in f... | 1-20. (canceled) 21. A product to help ensure compliance and optimize effectiveness in a treatment for minimizing the harmful effects of at least one of a malignant cancer tumor or virus, said product comprising the ingredients betaine, or its functional equivalent homolog, and vitamin C, or its functional equivalent, ... | Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors or to treat viruses, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or in f... | 1,600 |
844 | 844 | 12,093,912 | 1,634 | The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of pat... | 1. A method of karyotyping a human target cell to detect chromosomal imbalance therein, the method comprising:
(a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of paternal and maternal chromosomes to assemble a notional hap... | The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of pat... | 1,600 |
845 | 845 | 15,063,446 | 1,642 | The invention features methods of treating melanoma by modulating an activity of GDF6 in melanoma cells. In one aspect, the methods involve downregulating an activity of GDF6, for example, by using an anti-GDF6 binding molecule, such as an inactivating antibody. Another aspect features treating a subject by first scree... | 1. A method of treating a melanoma in a subject, the method comprising administering to a subject in need thereof an effective amount of an inhibitor of at least one GDF6 activity. 2. The method of claim 1, wherein the subject is a non-human mammal. 3. The method of claim 1, wherein the subject is a human. 4. The metho... | The invention features methods of treating melanoma by modulating an activity of GDF6 in melanoma cells. In one aspect, the methods involve downregulating an activity of GDF6, for example, by using an anti-GDF6 binding molecule, such as an inactivating antibody. Another aspect features treating a subject by first scree... | 1,600 |
846 | 846 | 14,521,351 | 1,633 | The present invention provides, among other things, methods of treating Argininosuccinate Synthetase Deficiency (ASD), including administering to a subject in need of treatment a composition comprising an mRNA encoding argininosuccinate synthetase (ASS1) at an effective dose and an administration interval such that at ... | 1. A method of treating Argininosuccinate Synthetase Deficiency (ASD), comprising administering to a subject in need of treatment a composition comprising an mRNA encoding argininosuccinate synthetase (ASS1) at an effective dose and an administration interval such that at least one symptom or feature of ASD is reduced ... | The present invention provides, among other things, methods of treating Argininosuccinate Synthetase Deficiency (ASD), including administering to a subject in need of treatment a composition comprising an mRNA encoding argininosuccinate synthetase (ASS1) at an effective dose and an administration interval such that at ... | 1,600 |
847 | 847 | 15,008,937 | 1,617 | A preservative composition is described that may be used in personal care products and other products for protecting the products against bacteria and fungus during production and during use. The composition can about 3 to about 15% by weight of an organic acid; about 3 to about 15% by weight of a C 8 -C 18 fatty alco... | 1. A fluid preservative composition comprising
(i) about 3 to about 15% by weight of an organic acid; (ii) about 3 to about 15% by weight of a C8-C18 fatty alcohol; (iii) about 30 to about 60% by weight of an aromatic alcohol; and (iv) about 30 to about 60% by weight of an organic solvent. 2. The preservative compositi... | A preservative composition is described that may be used in personal care products and other products for protecting the products against bacteria and fungus during production and during use. The composition can about 3 to about 15% by weight of an organic acid; about 3 to about 15% by weight of a C 8 -C 18 fatty alco... | 1,600 |
848 | 848 | 15,764,089 | 1,619 | A sunscreen cosmetic eliminates instability of a dibenzoylmethane derivative that is a UVA absorbing-agent, which exhibits excellent ultraviolet radiation protection performance across a wide wavelength region from UVA to UVB, and which exhibits excellent light resistance, is stable over time, and does not suffer from ... | 1.-12. (canceled) 13. A sunscreen cosmetic, comprising:
(a) a dibenzoylmethane derivative; and (b) a powder that is surface-hydrophobized by treatment with a metal soap consisting of a higher fatty acid and an alkaline earth metal, or by a combination treatment with a higher fatty acid and an alkaline earth metal hydro... | A sunscreen cosmetic eliminates instability of a dibenzoylmethane derivative that is a UVA absorbing-agent, which exhibits excellent ultraviolet radiation protection performance across a wide wavelength region from UVA to UVB, and which exhibits excellent light resistance, is stable over time, and does not suffer from ... | 1,600 |
849 | 849 | 15,603,267 | 1,628 | Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and... | 1. The method of claim 15, wherein the 3α-hydroxy-5α-pregnan-20-one, a derivative or analog thereof, or a pharmaceutically acceptable salt thereof is formulated as a pharmaceutical composition for systemic administration via a route selected from the group consisting of transdermal administration, subcutaneous injectio... | Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and... | 1,600 |
850 | 850 | 14,896,294 | 1,633 | The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×10 1... | 1. A method of treating a human patient, said method comprising the steps of:
systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each administration is in the range of 1×1010 to 1×... | The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×10 1... | 1,600 |
851 | 851 | 14,906,507 | 1,618 | The disclosure relates generally to ionic salts, particularly low-melting ionic salts such as ionic liquids, of poorly-water soluble drugs. The disclosure further relates to methods of preparing the ionic salts of poorly-water soluble drugs, lipid formulations comprising them and their use in drug delivery. | 1.-31. (canceled) 32. A lipid formulation of a poorly water soluble drug comprising a low melting ionic salt of the poorly water soluble drug, together with a substantially non-aqueous lipid vehicle. 33. The lipid formulation according to claim 32 wherein the low melting ionic salt is a ionic liquid salt of the poorly ... | The disclosure relates generally to ionic salts, particularly low-melting ionic salts such as ionic liquids, of poorly-water soluble drugs. The disclosure further relates to methods of preparing the ionic salts of poorly-water soluble drugs, lipid formulations comprising them and their use in drug delivery.1.-31. (canc... | 1,600 |
852 | 852 | 14,402,590 | 1,624 | A composition is provided with a benzodiazepine and at least one hygroscopic excipient, in particular lactose and/or dextran. | 1-39. (canceled) 40. A lyophilized or spray-dried composition comprising at least one benzodiazepine according to formula (I)
with
W is H;
X is CH2; n is 1;
Y is CH2; m is 1;
Z is O; p is 0 or 1;
R1 is CH3, CH2CH3, CH2CH2CH3, CH(CH3)2 or CH2CH(CH3)2;
R2 is 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl;
R3 is Cl... | A composition is provided with a benzodiazepine and at least one hygroscopic excipient, in particular lactose and/or dextran.1-39. (canceled) 40. A lyophilized or spray-dried composition comprising at least one benzodiazepine according to formula (I)
with
W is H;
X is CH2; n is 1;
Y is CH2; m is 1;
Z is O; p ... | 1,600 |
853 | 853 | 15,069,672 | 1,699 | The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding do... | 1) A method for targeting and processing a double-stranded DNA, comprising:
(a) selecting one DNA target sequence of interest on one strand of a double-stranded DNA; (b) providing a unique compact TALEN monomer comprising:
(i) one core TALE scaffold comprising Repeat Variable Dipeptide regions (RVDs) having DNA binding... | The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding do... | 1,600 |
854 | 854 | 14,783,295 | 1,658 | The present invention has an object of providing a novel drug inhibiting formation of leukocyte extracellular traps. The present invention provides a lactoferrin-containing inhibitor of formation of leukocyte extracellular traps, and a lactoferrin-containing composition for treating a disease associated with the format... | 1. A method for treating a disease associated with formation of leukocyte extracellular traps, comprising administering a composition for inhibiting formation of leukocyte extracellular traps to a patient in need thereof, wherein said composition comprises lactoferrin and pharmacologically acceptable carrier, and said ... | The present invention has an object of providing a novel drug inhibiting formation of leukocyte extracellular traps. The present invention provides a lactoferrin-containing inhibitor of formation of leukocyte extracellular traps, and a lactoferrin-containing composition for treating a disease associated with the format... | 1,600 |
855 | 855 | 15,259,862 | 1,612 | Provided is a non-aqueous formulation for oral teeth, which includes a source of a metal ion and a source of a phosphate ion. The metal ion is chosen from alkaline earth metals, Zn, Zr or any combination thereof, and a molar ratio of the metal ion to the phosphate ion in the formulation is between about 0.01 and about ... | 1. A method for treating or preventing an exposed dentinal tubule-associated symptom or disease, comprising administering a non-aqueous formulation to dentinal tubules of a subject in need thereof, wherein the non-aqueous formulation comprises:
a source of a metal ion; and a source of a phosphate ion, wherein the metal... | Provided is a non-aqueous formulation for oral teeth, which includes a source of a metal ion and a source of a phosphate ion. The metal ion is chosen from alkaline earth metals, Zn, Zr or any combination thereof, and a molar ratio of the metal ion to the phosphate ion in the formulation is between about 0.01 and about ... | 1,600 |
856 | 856 | 14,629,859 | 1,662 | Materials and methods for gene targeting using Clustered Regularly Interspersed Short Palindromic Repeats/CRISPR-associated (CRISPR/Cas) systems are provided herein. | 1. A method for modifying the genomic material in a plant cell, comprising:
(a) introducing into the plant cell a nucleic acid molecule, wherein the nucleic acid molecule comprises a crRNA and a tracrRNA, a chimeric cr/tracrRNA hybrid, a sequence encoding the crRNA and the tracrRNA, or a sequence encoding the chimeric ... | Materials and methods for gene targeting using Clustered Regularly Interspersed Short Palindromic Repeats/CRISPR-associated (CRISPR/Cas) systems are provided herein.1. A method for modifying the genomic material in a plant cell, comprising:
(a) introducing into the plant cell a nucleic acid molecule, wherein the nuclei... | 1,600 |
857 | 857 | 14,774,886 | 1,619 | Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anx... | 1. A method of treating a condition in a subject, comprising treating the condition by administering to the subject a composition comprising a Glo1 inhibitor, wherein the condition is a sleep disorder or mood disorder. 2. The method of claim 1, wherein the condition is a sleep disorder. 3. The method of claim 2, wherei... | Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anx... | 1,600 |
858 | 858 | 15,192,708 | 1,631 | The present invention describes a method that is comprised of creating a set of synthetic samples that mimic a dynamic process or a specific process step or a variation thereof, to be used to develop multivariate monitoring calibrations and process supervisory control systems. | 1. A method for preparing at least one synthetic multicomponent biotechnological and/or chemical process sample for developing multivariate calibrations for monitoring systems and/or multivariate supervisory systems of increased robustness, wherein at least one synthetic sample mimicking a dynamic process or a specific... | The present invention describes a method that is comprised of creating a set of synthetic samples that mimic a dynamic process or a specific process step or a variation thereof, to be used to develop multivariate monitoring calibrations and process supervisory control systems.1. A method for preparing at least one synt... | 1,600 |
859 | 859 | 14,785,548 | 1,618 | The invention relates to preparations for dietary, food supplement or medical purposes and more specifically to a safe and natural preparation or a composition useful in immunity regulation and/or stimulation and in particular in the building, reinforcement, efficiency, maintenance and regeneration of natural immune de... | 1. A composition for immunity regulation and/or stimulation, per 100 g or 100 ml, comprising the combination of:
10 μg to 1000 μg of positively charged minerals consisting of magnesium, 10 μg to 1000 μg of metals selected from zinc and iron 7 μg to 700 μg of at least one plant oil selected from Ribes nigrum Oleum Acini... | The invention relates to preparations for dietary, food supplement or medical purposes and more specifically to a safe and natural preparation or a composition useful in immunity regulation and/or stimulation and in particular in the building, reinforcement, efficiency, maintenance and regeneration of natural immune de... | 1,600 |
860 | 860 | 13,989,351 | 1,644 | The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination. | 1. A method of preparing a peptide or polypeptide comprising an artificial sequence able to activate NKT cells, said method comprising the steps of:
(a) identifying a peptide or polypeptide that does not activate NKT cells; (b) introducing into the peptide or polypeptide at least one CD1d binding motif by aminoacid add... | The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination.1. A method of preparing a peptide or polypeptide comprising an artificial sequence able to activate ... | 1,600 |
861 | 861 | 15,315,557 | 1,644 | The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administ... | 1. A method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject having a serum vitamin-D level above 50 nanomole/liter. 2. The method according to claim 1, wherein the beta cell autoantigen is sele... | The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administ... | 1,600 |
862 | 862 | 12,640,861 | 1,653 | The present invention relates to apparatus, methods, and applications for treating wastewater, and more particularly to biological processes for removing pollutants from wastewater. This invention further relates to apparatus and methods for growing microbes on-site at a wastewater treatment facility, and for economica... | 1-73. (canceled) 74. A method of reducing the time required for a wastewater treatment plant for coming into compliance with an environmental discharge regulation comprising:
providing an on-site system for growing of microbes at the wastewater treatment plant, the on-site system comprising: a main tank, an input for w... | The present invention relates to apparatus, methods, and applications for treating wastewater, and more particularly to biological processes for removing pollutants from wastewater. This invention further relates to apparatus and methods for growing microbes on-site at a wastewater treatment facility, and for economica... | 1,600 |
863 | 863 | 14,764,488 | 1,618 | A method of treating a fungal infection in a subject includes topically administering to the subject a therapeutically effective amount of a fungal iron acquisition inhibitor to treat fungal infection in the subject. | 1-27. (canceled) 28. A method of treating a corneal fungal infection in a subject comprising:
topically administering to the subject a therapeutically effective amount of a fungal iron acquisition inhibitor to treat corneal fungal infection in the subject. 29. The method of claim 28, the fungal iron acquisition inhibit... | A method of treating a fungal infection in a subject includes topically administering to the subject a therapeutically effective amount of a fungal iron acquisition inhibitor to treat fungal infection in the subject.1-27. (canceled) 28. A method of treating a corneal fungal infection in a subject comprising:
topically ... | 1,600 |
864 | 864 | 14,113,740 | 1,644 | Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limit... | 1. A method for diagnosing a Multiple Sclerosis (MS) in a human being, comprising:
a). providing a sample of peripheral blood mononuclear cells (PBMCs) from blood, and serum or plasma of said human being; b). exposing said sample of PBMCs and serum or plasma to a CNS antigen associated with Multiple Sclerosis (MS); and... | Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limit... | 1,600 |
865 | 865 | 14,703,337 | 1,627 | Antimicrobial diferulates, compositions containing same, and uses of same for inhibiting growth of microorganisms. The antimicrobial diferulates can be used alone or in combination with other antimicrobial agents to inhibit growth of microorganisms such as fungi, oomycetes, and other microorganisms having a glucan-cont... | 1. An antimicrobial composition comprising an antimicrobial-effective amount of a substantially purified compound selected from the group consisting of a compound of Formula I, a compound of Formula II, and combinations thereof, in combination with an inert carrier, wherein:
the compound of Formula I is selected from t... | Antimicrobial diferulates, compositions containing same, and uses of same for inhibiting growth of microorganisms. The antimicrobial diferulates can be used alone or in combination with other antimicrobial agents to inhibit growth of microorganisms such as fungi, oomycetes, and other microorganisms having a glucan-cont... | 1,600 |
866 | 866 | 15,096,214 | 1,633 | An improved method to kill pathogenic microbes in a patient is disclosed and claimed. The improved method includes transducing eukaryotic cells of the patient with a first viral vector that will not transfect the pathogenic microbes. The first viral vector is replication defective and encodes in its recombinant genome ... | 1. A method to kill pathogenic microbes in a patient, comprising:
transducing eukaryotic cells of the patient with a first viral vector that will not transfect the pathogenic microbes, the first viral vector is replication defective and encodes in its recombinant genome a first antimicrobial resistance gene and a first... | An improved method to kill pathogenic microbes in a patient is disclosed and claimed. The improved method includes transducing eukaryotic cells of the patient with a first viral vector that will not transfect the pathogenic microbes. The first viral vector is replication defective and encodes in its recombinant genome ... | 1,600 |
867 | 867 | 15,784,487 | 1,619 | Disclosed herein are foamable gritty foam compositions that can suspend particulate mechanical scrubbers with particles sized from about 100 microns to about 800 microns that is capable of being foamed through a non-aerosol, or unpressurized pump dispenser. | 1. A non-aerosol dispenser containing a foamable gritty composition, the non-aerosol dispenser comprising an unpressurized container having a dispenser pump configured to mix air with the foamable gritty composition under low pressure conditions during dispensing to form a gritty foam; and the foamable gritty compositi... | Disclosed herein are foamable gritty foam compositions that can suspend particulate mechanical scrubbers with particles sized from about 100 microns to about 800 microns that is capable of being foamed through a non-aerosol, or unpressurized pump dispenser.1. A non-aerosol dispenser containing a foamable gritty composi... | 1,600 |
868 | 868 | 13,131,506 | 1,629 | A human oral care composition, includes safe and effective amounts of the fluoride ion and stabilized chlorine dioxide, that may take the form of a paste, gel, rinse, spray, powder, varnish or similar that reduces demineralization and promotes remineralization of teeth. The method includes the topical application of th... | 1. A composition for reducing demineralization and promoting remineralization of teeth, said compensation comprising in combination:
a) a chlorine dioxide source; b) a fluoride ion source; and c) a buffer. 2. The composition as set forth in claim 1 wherein said chlorine dioxide source is stabilized chlorine dioxide. 3.... | A human oral care composition, includes safe and effective amounts of the fluoride ion and stabilized chlorine dioxide, that may take the form of a paste, gel, rinse, spray, powder, varnish or similar that reduces demineralization and promotes remineralization of teeth. The method includes the topical application of th... | 1,600 |
869 | 869 | 15,484,509 | 1,699 | A method for detecting soluble oligomeric amyloid β in a subject using, e.g., PET is provided. | 1. A kit for detecting soluble oligomeric amyloid β comprising
(a) an antibody or fragment thereof that selectively binds soluble oligomeric amyloid β, and either
(b) a labeling moiety selected from the group of:
(i) a chelating agent, and
(ii) a fluorescent label; or
(c) a labeled secondary antibody. 2. The kit of cl... | A method for detecting soluble oligomeric amyloid β in a subject using, e.g., PET is provided.1. A kit for detecting soluble oligomeric amyloid β comprising
(a) an antibody or fragment thereof that selectively binds soluble oligomeric amyloid β, and either
(b) a labeling moiety selected from the group of:
(i) a chelati... | 1,600 |
870 | 870 | 14,771,192 | 1,612 | The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester s... | 1. An anhydrous transdermal composition comprising
at least one active ingredient optionally (a) having a log P in hexane and water of less than about 8 at pH 7.4, or (b) being an anthelmintic, a terpene optionally present at, at least 20% by weight, and a solvent selected from
i) a non-hydroxyl containing solvent,
ii)... | The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester s... | 1,600 |
871 | 871 | 14,428,350 | 1,618 | The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising ... | 1. A poly(lactic-co-glycolic) acid (PLGA) particle comprising a perfluoro crown ether and a gadolinium chelate. 2. The particle of claim 1, wherein the perfluoro crown ether is selected from the group consisting of perfluoro-15-crown-5-ether, perfluoro-12-crown-4-ether, and perfluoro-18-crown-6-ether. 3. The particle o... | The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising ... | 1,600 |
872 | 872 | 14,130,718 | 1,629 | The present invention relates to a product comprising capsaicin or a capsaicinoid for use in the treatment of cough, in particular chronic persistent unexplained cough or increased cough reflex sensitivity. More precisely, the invention concerns oral formulations for reducing and relieving coughing from other irritants... | 1-10. (canceled) 11. A method of treating cough symptoms in a patient in need thereof, comprising administering to said patient a formulation comprising capsaicin and/or a capsaicinoid. 12. The method of claim 11, wherein cough symptoms comprise chronic persistent unexplained cough or increased cough reflex sensitivity... | The present invention relates to a product comprising capsaicin or a capsaicinoid for use in the treatment of cough, in particular chronic persistent unexplained cough or increased cough reflex sensitivity. More precisely, the invention concerns oral formulations for reducing and relieving coughing from other irritants... | 1,600 |
873 | 873 | 15,795,873 | 1,627 | Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent. | 1-10. (canceled) 11. A solid dispersion comprising a compound of formula (I):
in a water-soluble polymer selected from hydroxypropylmethyl cellulose and vitamin E TGPS. 12. The solid dispersion according to claim 11, wherein the polymer is hydroxypropylmethyl cellulose 2910 5 mPa·s. 13. The solid dispersion ... | Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent.1-10. (canceled) 11. A solid dispersion comprising a compound of formula (I):
in a water-soluble polymer selected from hydroxypropylmethyl cellulose and vitamin E TGPS. 12. The so... | 1,600 |
874 | 874 | 14,810,858 | 1,615 | Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may be designed to exhibit o... | 1. A method of making an implantable biomaterial for aiding bone regeneration, the method comprising:
obtaining demineralized bone in particulate form; adding the demineralized, particulate bone to a mold; compressing the demineralized, particulate bone in the mold for a time and pressure sufficient to form a molded bi... | Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may be designed to exhibit o... | 1,600 |
875 | 875 | 15,314,674 | 1,653 | The invention relates to a method for a photochemical process, such as a photocatalytic and/or photosynthetic process, in particular for the culture and production or the hydroculture of microorganisms. A reaction medium ( 6 ) is conducted in a meandering manner in a reactor element ( 2 ) which is made of at least two ... | 1-15. (canceled) 16. A method of culturing phototropic microorganisms in a reaction medium in a bioreactor, wherein the bioreactor comprises at least one reactor element, wherein the reactor element comprises an inlet for the reaction medium from outside of the reactor element, an outlet for the reaction medium to outs... | The invention relates to a method for a photochemical process, such as a photocatalytic and/or photosynthetic process, in particular for the culture and production or the hydroculture of microorganisms. A reaction medium ( 6 ) is conducted in a meandering manner in a reactor element ( 2 ) which is made of at least two ... | 1,600 |
876 | 876 | 11,668,148 | 1,653 | Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cel... | 1. A method of producing a mammal comprising the steps of:
obtaining sperm cells from a male of a nonhuman mammalian species; cryopreserving said obtained sperm cells; thawing said cryopreserved sperm cells; processing said thawed sperm cells; cryopreserving said processed sperm cells to yield twice-cryopreserved ... | Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cel... | 1,600 |
877 | 877 | 15,678,823 | 1,635 | The present invention relates to a siRNA structure and the use thereof. More particularly, the invention relates to a double-stranded small interfering RNA molecule (siRNA molecule) comprising a 19-21 nucleotide (nt) antisense strand and a 15-19 nt sense strand having a sequence complementary to the antisense sequence,... | 1. A small interfering RNA molecule (siRNA molecule) comprising: a 19-21 nucleotide (nt) antisense strand; and a 15-19 nt sense strand having a sequence complementary to the antisense strand, wherein the 5′ end of the antisense strand has a blunt end and the 3′ end of the antisense strand has an overhang. 2. The siRNA ... | The present invention relates to a siRNA structure and the use thereof. More particularly, the invention relates to a double-stranded small interfering RNA molecule (siRNA molecule) comprising a 19-21 nucleotide (nt) antisense strand and a 15-19 nt sense strand having a sequence complementary to the antisense sequence,... | 1,600 |
878 | 878 | 14,901,617 | 1,644 | Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein provided. | 1. A method of inducing immune tolerance to at least one myelin sheath protein in a patient comprising administering to the patient an effective amount of a composition comprising a dendritic cell targeting complex comprising a dendritic cell antibody, or targeting fragment thereof, attached to the at least one myelin ... | Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein provided.1. A method of inducing immune tolerance to at least one myelin sheath protein in a patient comprising administering to the patient an effecti... | 1,600 |
879 | 879 | 13,865,121 | 1,639 | A method of tissue analysis integrates a pathology diagnostic step (subjective human inspection of a stained tissue section or image of it) with one or more gene/biomarker tests to enable perform of both procedures side-by-side on the same instrument. | 1. A method of operating an automated microscopy system for measuring biomarker labels, comprising:
labeling tissue sections with fluorescent labels for molecules; an automated microscopy-executed step of acquiring images of the fluorescently-labeled tissue sections; an automated microscopy-executed step of labeling th... | A method of tissue analysis integrates a pathology diagnostic step (subjective human inspection of a stained tissue section or image of it) with one or more gene/biomarker tests to enable perform of both procedures side-by-side on the same instrument.1. A method of operating an automated microscopy system for measuring... | 1,600 |
880 | 880 | 14,430,724 | 1,631 | The present invention provides a device, method, and program for detection of a biomarker candidate that may be used in a diagnosis of a pre-disease state indicating a transition from a healthy state to a disease state. Biological samples are collected from a subject to be measured at different times. Statistical data ... | 1. A device for detecting a candidate for a biomarker based on measurement data on a plurality of factors obtained in measurement on a biological object to be measured, the biomarker being an index of a symptom of the biological object, said device comprising:
classification means for classifying factors into clusters ... | The present invention provides a device, method, and program for detection of a biomarker candidate that may be used in a diagnosis of a pre-disease state indicating a transition from a healthy state to a disease state. Biological samples are collected from a subject to be measured at different times. Statistical data ... | 1,600 |
881 | 881 | 13,985,536 | 1,612 | Flavour components for use in oral care compositions containing a metal salt, compositions comprising the flavour components, and methods of making and using the same. The flavour components comprise a taste -masking agent comprising cinnamic aldehyde, eugenol and eucalyptol and one or more flavouring agents selected f... | 1. A flavor component for use in an oral care composition containing a metal salt, comprising:
a taste-masking agent comprising: cinnamic aldehyde; eugenol; and eucalyptol; and one or more flavoring agents selected from: L-menthol; N-ethyl-para-menthan-3-carboxamide; anethole; peppermint oil; spearmint oil; corn mint ... | Flavour components for use in oral care compositions containing a metal salt, compositions comprising the flavour components, and methods of making and using the same. The flavour components comprise a taste -masking agent comprising cinnamic aldehyde, eugenol and eucalyptol and one or more flavouring agents selected f... | 1,600 |
882 | 882 | 15,661,658 | 1,644 | The present invention relates to anti-human OX40L antibodies, new medical uses and methods. | 1-30. (canceled) 31. A method of decreasing IL-2 secretion in a human subject, comprising administering to the subject an anti-OX40L antibody or antibody fragment that:
i. antagonizes specific binding of OX40 to OX40L; and ii. comprises an IgG4 constant region; wherein the anti-OX40L antibody or antibody fragment is ad... | The present invention relates to anti-human OX40L antibodies, new medical uses and methods.1-30. (canceled) 31. A method of decreasing IL-2 secretion in a human subject, comprising administering to the subject an anti-OX40L antibody or antibody fragment that:
i. antagonizes specific binding of OX40 to OX40L; and ii. co... | 1,600 |
883 | 883 | 14,649,109 | 1,612 | Described herein are oral care compositions comprising a zinc ion source, a fluoride ion source, and a basic amino acid; along with methods of making and using the same. | 1. An oral care composition comprising:
from about 0.05 to about 5% by weight, of a zinc ion source; a fluoride ion source in an amount effective to deliver from about 500 to about 5,000 ppm fluoride, and from about 0.1 to about 10%, by weight, of a basic amino acid. 2. The composition of claim 1 wherein the zinc ion s... | Described herein are oral care compositions comprising a zinc ion source, a fluoride ion source, and a basic amino acid; along with methods of making and using the same.1. An oral care composition comprising:
from about 0.05 to about 5% by weight, of a zinc ion source; a fluoride ion source in an amount effective to de... | 1,600 |
884 | 884 | 16,223,940 | 1,617 | Packaged formulations of gamma-hydroxybutyrate having improved dissolution and chemical stability, packaging for supporting said stability, and therapeutic uses thereof. | 1. A packaged pharmaceutical composition comprising a pharmaceutical composition within a package, the pharmaceutical composition comprising:
a. an immediate release component comprising gamma-hydroxybutyrate or a pharmaceutically acceptable salt thereof; and b. a modified release component comprising gamma-hydroxybuty... | Packaged formulations of gamma-hydroxybutyrate having improved dissolution and chemical stability, packaging for supporting said stability, and therapeutic uses thereof.1. A packaged pharmaceutical composition comprising a pharmaceutical composition within a package, the pharmaceutical composition comprising:
a. an imm... | 1,600 |
885 | 885 | 15,109,746 | 1,641 | Methods and devices electrochemically detect analytes. The methods employ metal particles conjugated to the analytes. The metal particles can serve as an electrochemical label for the analyte to which they are conjugated. The metal particles can be oxidized to form metal ions that can subsequently be electrochemically ... | 1. A method for detecting an analyte comprising:
(a) flowing fluid along a channel while applying a magnetic field to a region of the channel in electrochemical contact with a working electrode in order to accumulate the analyte conjugated to a metal particle and a magnetic particle in the region of the channel; (b) ox... | Methods and devices electrochemically detect analytes. The methods employ metal particles conjugated to the analytes. The metal particles can serve as an electrochemical label for the analyte to which they are conjugated. The metal particles can be oxidized to form metal ions that can subsequently be electrochemically ... | 1,600 |
886 | 886 | 13,697,578 | 1,628 | Theobromine for use in the treatment of increasing HDL-cholesterol and/or increasing the ratio HDL-cholesterol:LDL-cholesterol in humans and the use of theobromine for increasing HDL-cholesterol in humans, and/or for increasing the ratio HDL-C/LDL-C, and compositions comprising theobromine. | 1. Theobromine for use in the treatment of improving blood lipids. 2. Theobromine for use in the treatment of increasing HDL-cholesterol in humans. 3. Theobromine for use in the treatment of increasing the ratio HDL-cholesterol/LDL-cholesterol in humans. 4. Theobromine for use in the treatment of increasing the ratio H... | Theobromine for use in the treatment of increasing HDL-cholesterol and/or increasing the ratio HDL-cholesterol:LDL-cholesterol in humans and the use of theobromine for increasing HDL-cholesterol in humans, and/or for increasing the ratio HDL-C/LDL-C, and compositions comprising theobromine.1. Theobromine for use in the... | 1,600 |
887 | 887 | 15,396,207 | 1,619 | Novel hybrid coating compositions for mammalian nails, systems comprising the compositions, kits containing these compositions or systems, and methods of their use are disclosed. The novel compositions and/or kits are useful, inter alia, for providing durable, “soak-off” type nail coatings. | 1. A hybrid nail coating system comprising: a first layer comprising a solvent, a film former, and a photoinitiator, the photoinitiator comprising a self-initiating oligomer. 2. The hybrid nail coating system according to claim 1, wherein the self-initiating oligomer comprises a moiety selected from the group consistin... | Novel hybrid coating compositions for mammalian nails, systems comprising the compositions, kits containing these compositions or systems, and methods of their use are disclosed. The novel compositions and/or kits are useful, inter alia, for providing durable, “soak-off” type nail coatings.1. A hybrid nail coating syst... | 1,600 |
888 | 888 | 14,980,374 | 1,611 | A method of treatment of a patient suffering from postoperative inflammatory stress and pain caused by mechanical impact exerted on portions of the body of the patient that causes damaged tissue wherein the inflammatory stress and pain of the operation outlast the healing of damaged tissue and which is not related to, ... | 1. A method of treatment of a patient suffering from postoperative inflammatory stress and pain caused by mechanical impact exerted on portions of the body of the patient that causes damaged tissue wherein the inflammatory stress and pain of the operation outlast the healing of damaged tissue and which is not related t... | A method of treatment of a patient suffering from postoperative inflammatory stress and pain caused by mechanical impact exerted on portions of the body of the patient that causes damaged tissue wherein the inflammatory stress and pain of the operation outlast the healing of damaged tissue and which is not related to, ... | 1,600 |
889 | 889 | 15,198,306 | 1,612 | A consumer product including a personal care composition providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules. | 1. A consumer product comprising a composition, the composition comprising:
an adjunct material;
a first population of microcapsules, the first population having a first median volume weighted particle size and comprising microcapsules comprising a partitioning modifier and a first perfume oil at a first weight ratio; ... | A consumer product including a personal care composition providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules.1. A consumer product comprising a composition, the composition comprising:
an adjunct material;
a first population of microcapsules, the firs... | 1,600 |
890 | 890 | 15,626,021 | 1,636 | Gene expression can be identified by analyzing a DNA sequence. The DNA sequence can include a barcode sequence that corresponds to a particular gene. The barcode sequence can be produced during the expression of a gene by first adding a Homologous Directed Repair (HDR) template including the barcode sequence into the D... | 1. A method comprising:
producing a first homology directed repair (HDR) template including at least a first splicing region and a barcode region, the first splicing region including a first sequence of nucleotides that is recognized by an enzyme to produce a cut in the first splicing region and the barcode region incl... | Gene expression can be identified by analyzing a DNA sequence. The DNA sequence can include a barcode sequence that corresponds to a particular gene. The barcode sequence can be produced during the expression of a gene by first adding a Homologous Directed Repair (HDR) template including the barcode sequence into the D... | 1,600 |
891 | 891 | 15,570,118 | 1,628 | The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions. | 1-48. (canceled) 49. A method for preventing or treating at least one symptom of Tourette syndrome in a human subject in need thereof, comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition comprising at least one cannabinoid or a salt thereof, and at least one N-acyl... | The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.1-48. (canceled) 49. A method for preventing or treating at least one symptom of Tourette syndrome in a human sub... | 1,600 |
892 | 892 | 12,688,193 | 1,639 | A method of determining a number of a solution constituent includes introducing a first number of solution constituents to a first test location, establishing a first binding environment for the introduced first number of solution constituents, creating a first residual number of solution constituents by binding a firs... | 1. A method of determining a number of a solution constituent comprising:
introducing a first number of solution constituents to a first test location; creating a first residual number of solution constituents by binding a first plurality of solution constituents at the first test location; creating a second residual n... | A method of determining a number of a solution constituent includes introducing a first number of solution constituents to a first test location, establishing a first binding environment for the introduced first number of solution constituents, creating a first residual number of solution constituents by binding a firs... | 1,600 |
893 | 893 | 13,945,438 | 1,619 | The invention relates to an aqueous transparent oil-in-water emulsion comprising a carotenoid and a process for producing said emulsion. | 1. An aqueous transparent oil-in-water emulsion comprising an emulsified carotenoid in a concentration of 0.025-2000 ppm. 2. The emulsion according to claim 1 whereby the carotenoid is selected from the group consisting of: cantaxanthin, astaxanthin, lutein, zeaxanthin, beta-zeacaroten, lycopene, apocarotenal, bixin, p... | The invention relates to an aqueous transparent oil-in-water emulsion comprising a carotenoid and a process for producing said emulsion.1. An aqueous transparent oil-in-water emulsion comprising an emulsified carotenoid in a concentration of 0.025-2000 ppm. 2. The emulsion according to claim 1 whereby the carotenoid is... | 1,600 |
894 | 894 | 14,388,575 | 1,646 | The invention provides methods of treating neoplasia, for example bladder cancer, by administering an IL-2 fusion protein and one or more therapeutic agents, where the IL-2 fusion protein does not necessarily have to target the neoplasia. | 1. A method of ameliorating cancer in a subject comprising:
administering an effective amount of an IL-2 fusion protein and one or more therapeutic agents to the subject in need thereof, thereby ameliorate the cancer. 2. The method of claim 1, wherein the IL-2 fusion protein does not specifically target or bind to the ... | The invention provides methods of treating neoplasia, for example bladder cancer, by administering an IL-2 fusion protein and one or more therapeutic agents, where the IL-2 fusion protein does not necessarily have to target the neoplasia.1. A method of ameliorating cancer in a subject comprising:
administering an effec... | 1,600 |
895 | 895 | 12,387,977 | 1,619 | A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-mill... | 1. A blend for forming into a pharmaceutical tablet comprising crystals of a medicinally active ingredient having a particle size less than about 40 μm and a dissolution aid, wherein said blend has been sufficiently milled to substantially coat said crystals with said dissolution aid, whereby the dissolution rate of sa... | A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-mill... | 1,600 |
896 | 896 | 15,206,639 | 1,619 | An oil-in-water type emulsified cosmetic and a method of making can be prepared in a system not containing a silicone and is surprising produced without a wet-type dispersion apparatus by using a specific combination of the oil component constituting the oily phase and a hydrophobizing agent for a hydrophobized powder.... | 1. An oil-in-water type emulsified cosmetic composition, comprising:
an aqueous phase; an oily phase dispersed in the aqueous phase; and a powder dispersed in the oily phase; wherein the oily phase further comprises: (a) volatile hydrocarbon oil and (b) non-volatile hydrocarbon oil in a combined amount of 40% by mass o... | An oil-in-water type emulsified cosmetic and a method of making can be prepared in a system not containing a silicone and is surprising produced without a wet-type dispersion apparatus by using a specific combination of the oil component constituting the oily phase and a hydrophobizing agent for a hydrophobized powder.... | 1,600 |
897 | 897 | 15,100,407 | 1,613 | The present invention relates to the use of a nutritional composition having a low amount of protein, such as less than 1.8 g/100 kcal for administration to infants of non-obese and non-overweight mothers so as to reduce the risk of developing metabolic syndrome, increased weight gain, increased fat deposition, overwei... | 1. A method for reducing the risk of developing a disorder selected from the group consisting of metabolic syndrome, increased weight gain, increased fat deposition, overweight, obesity, insulin resistance, glucose intolerance and diabetes mellitus later in an infant's life comprising administering a nutritional compos... | The present invention relates to the use of a nutritional composition having a low amount of protein, such as less than 1.8 g/100 kcal for administration to infants of non-obese and non-overweight mothers so as to reduce the risk of developing metabolic syndrome, increased weight gain, increased fat deposition, overwei... | 1,600 |
898 | 898 | 15,500,493 | 1,613 | Technical Problem
A problem of the present invention is, in one aspect, to provide a capsule formulation including an active ingredient and the like that may deteriorate upon contacting an acid, wherein the capsule formulation makes it possible not to deteriorate the active ingredient and the like by a gastric ac... | 1. A capsule formulation, comprising:
an enteric capsule comprising a water soluble film forming polymer and gellan gum; an active ingredient; and an oil acceptable for pharmaceuticals or foods; wherein the active ingredient and the oil are encapsulated by the enteric capsule. 2. The capsule formulation according to cl... | Technical Problem
A problem of the present invention is, in one aspect, to provide a capsule formulation including an active ingredient and the like that may deteriorate upon contacting an acid, wherein the capsule formulation makes it possible not to deteriorate the active ingredient and the like by a gastric ac... | 1,600 |
899 | 899 | 14,855,814 | 1,631 | A method for predicting characteristics of a compound includes collecting a first experimental information database for characteristics of reference compounds according to a quantum phenomenon, collecting a simulation database for characteristics of the reference compounds according to the quantum phenomenon by applyin... | 1. A method for predicting a characteristic of a compound, the method comprising:
collecting a first experimental information database for characteristics of a plurality of reference compounds according to a quantum phenomenon; collecting a simulation database for characteristics of the plurality of reference compounds... | A method for predicting characteristics of a compound includes collecting a first experimental information database for characteristics of reference compounds according to a quantum phenomenon, collecting a simulation database for characteristics of the reference compounds according to the quantum phenomenon by applyin... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.